| P50 | author | Hagop Kantarjian | Q60394812 |
| | Srdan Verstovsek | Q64026418 |
| | Lucia Masarova | Q88691886 |
| P2093 | author name string | Wei Wang | |
| | Kate J Newberry | |
| P2860 | cites work | Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis | Q33391880 |
| | JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis | Q33399977 |
| | A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis | Q33399980 |
| | Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. | Q33419957 |
| | Outcome of transplantation for myelofibrosis | Q34015474 |
| | IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. | Q34562170 |
| | IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F | Q35835653 |
| | The human androgen receptor X-chromosome inactivation assay for clonality diagnostics of natural killer cell proliferations | Q35855505 |
| | The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis | Q36091279 |
| | The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. | Q40463923 |
| | Mutations and prognosis in primary myelofibrosis | Q44429606 |
| | Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. | Q53096529 |
| | JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib. | Q54270648 |
| | New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment | Q79802927 |
| | Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment | Q80866784 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | myelofibrosis | Q1752571 |
| P304 | page(s) | 877-880 | |
| P577 | publication date | 2016-06-20 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Complete remission in a patient with JAK2- and IDH2-positive myelofibrosis | |
| P478 | volume | 128 | |